Home › Non-Hodgkin Lymphoma › NCT07226843

A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers

RecruitingPhase 1

NOVA-BCL6-1, A First-in-Human, Multicenter Phase 1a/1b Study to Investigate Safety, Tolerability, Pharmacokinetics, and Efficacy of LY4584180 in Adult Participants With Previously Treated Hematologic Malignancies

Who can join

Ages 18 and older · All sexes

Full eligibility criteria

Inclusion Criteria:

* Has been treated for the following blood cancers and has received at least 2 prior lines of systemic therapy or not eligible for available therapy:

  * Diffuse large B-cell lymphoma - not otherwise specified
  * High-grade B-cell lymphoma
  * Diffuse large B-cell lymphoma - transformed from indolent lymphomas
  * Follicular large B-cell lymphoma
  * Follicular lymphoma
  * Other non-Hodgkin lymphoma
* Has measurable disease
* Has discontinued all previous treatments for cancer and has recovered from the immediate effects of therapy

Exclusion Criteria:

* Has an active second cancer
* Has known central nervous system (CNS) involvement by systemic lymphoma. Patients with previous treatment for CNS involvement who are neurologically stable and without evidence of active CNS disease may be eligible and enrolled if a compelling clinical rationale is provided by the Investigator and with documented Sponsor approval.
* Has known Cytomegalovirus infection. Participants with negative status are eligible
* Has known hepatitis B or C infection or uncontrolled HIV
* Has known significant heart disease

About the study

The main purpose of this study is to evaluate safety and efficacy, and measure how much LY4584180 gets into the bloodstream and how long it takes the body to eliminate it in patients with previously treated blood cancers. For each participant, the study could last about 9 months or possibly longer including screening.

What is being tested

LY4584180 (drug)
Rituximab (drug)

Sponsor: Eli Lilly and Company · Participants: 460 · Started: Apr 17, 2026

Contact the study team

Trial question or participation questions: 1-877-CTLILLY (1-877-285-4559) or · Phone: 1-317-615-4559

Official record on ClinicalTrials.gov — NCT07226843

Locations in the U.S.

Arizona	Mayo Clinic - Scottsdale, Scottsdale
California	City of Hope, Duarte University of California, Los Angeles (UCLA) - Medical Center, Los Angeles University of California, San Francisco (UCSF) - Helen Diller Family Comprehensive Cancer Center, San Francisco
Colorado	Colorado Blood Cancer Institute, Denver
Florida	University of Miami - Sylvester Cancer Center, Miami Florida Cancer Specialists - Sarasota, Sarasota
Georgia	Emory University Hospital, Atlanta
Massachusetts	Dana-Farber Cancer Institute, Boston Massachusetts General Hospital, Boston
Minnesota	Mayo Clinic - Rochester, Rochester
New York	Columbia University, New York University of Rochester, Rochester
Ohio	The Ohio State University (OSU), Columbus
Oregon	Oregon Health & Science University (OHSU), Portland (Not yet recruiting)
Tennessee	Sarah Cannon Research Institute, Nashville Vanderbilt University Medical Center, Nashville
Texas	Texas Oncology - DFW (Sammons CC), Dallas Baylor College of Medicine, Houston (Not yet recruiting)
Washington	University of Washington - Fred Hutchinson Cancer Center (Seattle Cancer Care Alliance), Seattle
Wisconsin	Froedtert Hospital and the Medical College of Wisconsin, Milwaukee

Conditions

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.